Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Summary

To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).

Timeline

Start

2012-06

Primary completion

2018-05

Completion

2018-08

Drugs

Indications